Abstract 4892
Background
Chronic myeloid leukemia is characterized by onco-protein BCR-ABL1 which is constitutively activated. This particularity allowed the development of the first specific tyrosine kinase inhibitor (TKI) which changed the course of this disease. However, resistance to TKI is still a growing clinical problem. The canonical mechanism of resistance is point mutation in ABL1 kinase domain (KD). After the introduction of second and third TKI, the presence of multiple mutations was grown and the clinical importance is still controversial.
Methods
We included 21 resistant patients with two BCR-ABL1 KD mutations detected by direct sequencing. 43% failed to two therapies, 8 to three and 4 failed only to imatinib. For two patients we had sequential samples. We cloned ABL1 region and sequenced minimum of 10 clones. In order to evaluate the frequency of false compound mutation we cloned sample with only T315I mutation, other with F317L and 1:1 dilution of both samples.
Results
We observed that 66.7% of double mutations detected by direct sequencing were compound mutations. Our ratio of false positive compound mutation was 9%. T315I plus other mutation was the most frequently compound mutation in our cohort. Patients who failed to more than one TKI had higher frequency of compound mutation. Analyzing sequential samples we observed mutated clones in samples up to 5 months earlier than direct sequencing. The frequency of clones harboring compound mutations with more than two missense mutations was low (6%), comparing with silent mutations, suggesting a limited tolerance for BCR-ABL1 KD missense mutations. The number of transition was higher than transversion. Among patients with compound mutations: 5/7 progressed to advanced phases presented compound mutation, 1/2 died, 5/8 achieved molecular response (MR) during second or third line therapy and 3/4 did not achieve MR (median follow up 26 months).
Conclusions
We did not find correlation between presence of compound mutation and probability to respond therapy or progression. Analyze higher number of sample is needed. Indeed, the importance to detect clones harboring high resistance mutation such T315I earlier could help the clinician to choose the therapy to avoid clone progression.
Clinical trial identification
Legal entity responsible for the study
Instituto Nacional do Câncer.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract